Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    16643994 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy
Conditions: Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Drug: cisplatin;   Drug: gemcitabine hydrochloride

Indicates status has not been verified in more than two years